Nuclear Medicine Therapy Shows Long-Term Effectiveness for Malignant Neuroendocrine Tumors Bookmark

Excerpt from the Society of Nuclear Medicine and Molecular Imaging:

“A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.

“While PRRT has been used for more than 20 years to treat patients with inoperable or metastatic somatostatin receptor–positive tumors, knowledge of long-term outcomes has been limited. A number of clinical studies have demonstrated PRRT’s efficacy, and the overall response rate (including complete response, partial response, minor response, and stable disease) is about 70-80 percent for the two most commonly used radiopharmaceuticals: yttrium-90 (⁹⁰Y)-DOTATOC (best suited for treating larger tumors) and lutetium-177 (¹⁷⁷Lu)-DOTATATE (preferred for smaller tumors). For patients who respond to PRRT, the prognosis is generally favorable, with a median time to disease progression of three to four years.”

Go to full article published by the Society of Nuclear Medicine and Molecular Imaging on April 26, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Many Elderly Patients with Metastatic Renal Cell Carcinoma Benefit from Targeted Therapies Bookmark

Article from Medical Xpress curated by Editor in Chief George Lundberg, MD, who notes: 

Ageism (bias against the elderly) is a real issue in the selection of patients to be included in clinical trials. A new study demonstrates how such bias may harm the elderly with renal cell carcinoma.

Go to full article published by Medical Xpress.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer Bookmark

Research paper from the Journal of the National Comprehensive Care Network curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published in the Journal of the National Comprehensive Care Network. 

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Using the Principles of Evolution to Treat and Prevent Cancer Bookmark

Excerpt:

“Cancer has been called malevolent. Devious. Even ingenious. It’s actually none of these. Cancer has no purpose or direction. As these wayward cells arise, they simply adapt to the environmental conditions of the tissues in which they exist. That concept, which springs from Charles Darwin’s theory of evolution, is guiding new approaches to fighting this common and deadly disease.

“In Darwinian evolution, organisms that are well-adapted to their environments flourish and crowd out those that aren’t. My colleagues and I believe that much the same thing happens with cancer in a process we call adaptive oncogenesis.”

Go to full article published by STAT on Jun 27, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.